Mitolactol - Eleison Pharmaceuticals
Alternative Names: Bromoalcohol; DBD; Dibromdicil; Dibromodulcitol; Elobromol; Metholactole; Mitolactol-Chinoin; NSC 104800; WR 138743Latest Information Update: 03 Oct 2025
At a glance
- Originator Chinoin
 - Class Antineoplastics; Peptides; Small molecules
 - Mechanism of Action Alkylating agents; DNA inhibitors; DNA synthesis inhibitors
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- Market Withdrawal Cancer
 - Discontinued Brain cancer; Cervical cancer
 
Most Recent Events
- 03 Oct 2025 Eleison Pharmaceuticals plans a pivotal phase III trial in Brain cancer in 2026 (Eleison Pharmaceuticals pipeline, September 2025)
 - 10 Dec 2020 Eleison has patent protection for Composition of matter in the US
 - 04 Dec 2019 Eleison Pharmaceuticals enters into a licensing agreement with Targent for the development and commercialisation of mitaloacol (Dibromodulcitol)